Former Sen. Ben Sasse Highlights Potential Breakthrough in Pancreatic Cancer Treatment
Former Senator Ben Sasse has brought attention to a potential breakthrough in pancreatic cancer treatment involving a drug called daraxonrasib, developed by Revolution Medicines. Sasse, who was diagnosed with Stage 4 pancreatic cancer, reported a significant reduction in his tumors after taking the drug. The company is preparing to release results from a Phase 3 trial, which could make daraxonrasib the first targeted treatment for pancreatic cancer, a disease with a notoriously low survival rate. The drug targets RAS mutations, which are present in the majority of pancreatic cancer cases. Despite promising results, the drug has side effects, including severe skin rashes, due to its broad activity against RAS proteins throughout the body. 
